Pricing Log in Create free account
Friday 6 November 2026 Export ARGX’s income statement to Excel — free account

argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.

Revenue
+52.1%
EPS
+43.9%
Free cash flow
+537.5%

Quarter to September 2026, against a year earlier

922.55 27.78 +3.10%
Market cap
$56.3B
P/E
29.8×
Fwd P/E
30.1×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

argenex SE (ARGX) Total debt

Alert me on Total debt

argenex SE's total debt at the end of fiscal 2022 was $11.7M, unchanged from fiscal 2021. At the end of the quarter to 30 June 2023 it was $7.6M. argenex SE ranks 258th of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2022 $11.7M 2.98%
FY2021 $11.4M 15.06%
FY2020 $9.9M 25.57%
FY2019 $7.9M —

Quarterly newest first

Period Total debt Change
Jun 2023 $7.6M (10.60%)
Dec 2022 $8.5M 36.17%
Jun 2022 $6.3M (21.43%)
Dec 2021 $8.0M 67.05%
5 more quarters

Total debt against peers

Company Total debt
RPRX Royalty Pharma PLC compare $8.6B
GMAB Genmab A/S Sponsored ADR compare $5.1B
REGN Regeneron Pharmaceuticals, Inc. compare $2.0B
RVMD Revolution Medicines, Inc. compare $1.0B
ONC BeOne Medicines Ltd. - Sponsored ADR compare $825.2M
MRNA Moderna, Inc. compare $597.0M
ROIV Roivant Sciences Ltd. compare $323.7M
INCY Incyte Corporation compare $27.6M
ARGX argenex SE $7.6M

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on ARGX